Ocugen is a clinical-stage biopharmaceutical company that develops gene therapies for blindness diseases like retinitis pigmentosa and leber congenital amaurosis. Their pipeline product includes OCU400, OCU410, and OCU200 for the treatment of a range of genetic retinal diseases and macular degeneration. The company has strategic partnerships with CanSino Biologics and Bharat Biotech and is headquartered in Malvern, Pennsylvania.